SecBot SecBot
SECBOTREPLAY Home › Report › XENE

XENE · Investor conference schedule

Xenon Pharmaceuticals Inc. · PRESS-RELEASE filed Nov 3, 2026 at 16:01 ET

At the news

NEUTRALIMPACT 2/10

PRESS-RELEASE filed Nov 3, 2026 at 16:01 ET

Xenon Pharmaceuticals announced its participation in four upcoming investor conferences in Q4 2026, with no financial results or material business updates disclosed. The press release is a routine corporate communication with no impact on the company's fundamentals.

  • Xenon will present at four investor conferences in Q4 2026: Guggenheim, Stifel, Jefferies, and Evercore.
  • No financial results, guidance, or material business developments were disclosed.
  • The company's lead molecule is azetukalner, a KV7 potassium channel opener in late-stage development for epilepsy and depression.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access